<DOC>
	<DOCNO>NCT01884441</DOCNO>
	<brief_summary>Test bendamustine combination gemcitabine vinorelbine could contribute high response rate reduction toxic side effect</brief_summary>
	<brief_title>Bendamustine , Gemcitabine Vinorelbine ( BeGEV ) Induction Therapy Relapsed/Refractory Hodgkin 's Lymphoma Patients</brief_title>
	<detailed_description>The aim study evaluate bendamustine , gemcitabine vinorelbine ( BeGEV ) scheme efficacy induction therapy high dose chemotherapy Allogeneic Hematopoietic Stem-Cell Transplantation ( AHSCT ) patient relapsed/refractory Hodglin 's Lymphoma ( HL ) . Four BeGEV course repeat every 3 week absence reason list paragraph 7.5 ; whenever objective response observe disease evaluation perform IV cycle patient undergo high dose chemotherapy AHSCT ( condition regimen base preference Centre ) .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>relapsed/refractory disease receive one line standard chemotherapy history classical Hodgkin 's Lymphoma ( HL ) Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 least one site measurable nodal disease baseline ≥ 1.5 cm Absolute Neutrophils Count ( ANC ) ≥ 1.5 x 109/L ; Platelets count ≥ 75 x 109/L Diagnosis Nodular lymphocyte predominant Hodgkin 's lymphoma ( NLPHL ) prior radiation therapy ≤ 3 week prior start study treatment concurrent anticancer therapy evidence another malignancy remission history malignancy within last 2 year . aspartate aminotransferase ( AST/SGOT ) and/or alanine aminotransferase ( ALT/SGPT ) ≥ 2.5 x upper limit normal ( ULN ) ≥ 5.0 x ULN transaminase elevation due disease involvement know history Human immunodeficiency virus ( HIV ) seropositivity hepatitis B virus ( HBV ) hepatitis B virus ( HCV ) active hepatitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Hodgkin</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>refractory</keyword>
	<keyword>relapse</keyword>
</DOC>